Post‐reflux swallow‐induced peristaltic wave index and mean nocturnal baseline impedance predict proton pump inhibitor response in patients with reflux hypersensitivity
Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1111/jgh.16718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Jie Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology o…. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Electric Impedance, Gastroesophageal Reflux, Peristalsis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: External Science and Technology Cooperation Planning Projects of Anhui Province of China.
Abstract (Originalsprache)
Background and Aim Post‐reflux swallow‐induced peristaltic wave (PSPW) index and mean nocturnal baseline impedance (MNBI) have been shown to influence proton pump inhibitor (PPI) response in GERD patients. However, currently, little data concerning these variables in patients with reflux hypersensitivity (RH) are available. In this study, we aimed to evaluate, in RH patients, the prevalence of PPI responders and nonresponders and investigate the predictive value of impedance–pH variables, including PSPW and MNBI, on responses to PPI.
Methods
A total of 108 RH patients who met ROME IV criteria were prospectively recruited from June 2018 to December 2022. The prevalence of PPI responders/nonresponders was calculated, and impedance–pH variables were compared between the response and nonresponse groups. Multiple logistic regression was used to investigate predictors for PPI response.
Results
Among 108 patients with RH, 60 patients (55.56%) were the PPI responders, and 48 (44.44%) were the nonresponders. Compared with the nonresponders, the PPI responders had a lower PSPW index (47.05 ± 4.43 vs 51.33 ± 3.50, P = 0.004) and a decreased value of MNBI (1866.68 ± 390.62 vs 2181.14 ± 338.42, P = 0.017). Multivariate logistic regression revealed that only the pathologic PSPW index (OR: 2.064) and MNBI (OR: 1.800) significantly influenced PPI response.
Conclusions
Nearly half of RH patients were PPI nonresponders. Impedance–pH monitoring was more valuable than pH‐only monitoring in associating PPI response to reflux in RH patients owing to the appraisal of the PSPW index and MNBI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
- Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Förderung
- External Science and Technology Cooperation Planning Projects of Anhui Province of China
Zitieren
APA
Liu, J., Yin, M., Lv, C., Wang, W., Huang, Y., Tian, J., Wang, B., Song, G., & Yu, Y. (2024). Post‐reflux swallow‐induced peristaltic wave index and mean nocturnal baseline impedance predict proton pump inhibitor response in patients with reflux hypersensitivity. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16718
Vancouver
Liu J, Yin M, Lv C, Wang W, Huang Y, Tian J, et al. Post‐reflux swallow‐induced peristaltic wave index and mean nocturnal baseline impedance predict proton pump inhibitor response in patients with reflux hypersensitivity. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16718
BibTeX
@article{Liu2024,
author = {Liu, Jie and Yin, Mengqing and Lv, Chaolan and Wang, Wei and Huang, Yizhou and Tian, Jiashuang and Wang, Bo and Song, Gengqing and Yu, Yue},
title = {Post‐reflux swallow‐induced peristaltic wave index and mean nocturnal baseline impedance predict proton pump inhibitor response in patients with reflux hypersensitivity},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1111/jgh.16718}
}
EUVIMED